Beyond the Colored Brain Map: Scientific Literacy for Users and Critics of Neurotechnology

 

A colored fMRI image can appear to show thought, fear, memory, trauma, or disease directly. It does not. Functional neuroimaging is valuable, but its images are indirect physiological measurements—not photographs of the mind.

The recent video “Neuroscience is in big trouble” makes an important point, even if its title is too sweeping: a measurement must not be confused with the phenomenon it is intended to represent. 

What fMRI measures

Most fMRI studies rely on the blood-oxygen-level-dependent, or BOLD, signal. BOLD reflects changes in blood oxygenation, blood flow, blood volume, and metabolism associated with neural activity.

The signal can be scientifically useful, but it does not directly measure action potentials, a neurotransmitter, a unique psychological state, or the personal meaning of an experience. Its interpretation depends on neurovascular coupling, which may vary by brain region, vascular characteristics, age, medications, disease, task conditions, and baseline physiological state. 

This means that a larger BOLD response does not automatically prove “more neural activity,” and activation in one brain region does not prove one specific emotion or cognitive process. Recent evidence also suggests that BOLD changes and oxygen metabolism may diverge in some cortical areas, especially in default-mode-network regions. 

Why interpretation becomes risky

The problem is often not the technology itself, but the claim built upon it.

A highlighted amygdala is frequently interpreted as proof of fear. Yet the amygdala is also involved in salience, attention, learning, uncertainty, value, social processing, and autonomic regulation. Inferring a specific mental process merely because an associated region is active is called reverse inference.

Similarly, a statistical difference between patient and control groups does not automatically create a diagnostic biomarker for an individual. For a neuroimaging marker to become clinically useful, it must show adequate reliability, replication, external validation, diagnostic discrimination, and improvement in real clinical decisions. These standards remain difficult to meet in many psychiatric and translational fMRI applications because signals vary within and between people, sites, scanners, and analytic pipelines.

Lessons for users

When reading an fMRI study or encountering a commercial “brain-based” claim, ask:

• What was actually measured: BOLD contrast, blood flow, anatomy, electrical activity, or behavior?
• Is the conclusion correlational or genuinely causal?
• Is the result based on group averages or does it predict outcomes in individuals?
• Has it been replicated in independent samples and across research sites?
• Are there converging data from behavior, clinical assessment, EEG/MEG, PET, physiology, lesion studies, or longitudinal follow-up?

The more specific and clinically consequential the claim—such as diagnosing PTSD, predicting treatment response, or explaining a person’s behavior—the greater the need for independent and multimodal evidence.

Lessons for critics

Criticism is necessary. It is appropriate to challenge small samples, flexible analytic decisions, weak reliability, overlocalization, reverse inference, and causal language based on correlational data.

But an indirect measure is not automatically a useless measure. Medicine often uses proxies: blood pressure is not vascular pathology itself, and a laboratory value is not identical to the disease process it helps assess. Similarly, BOLD imaging can contribute meaningful evidence when its assumptions and uncertainty are explicit and when findings converge with other methods.

The appropriate criticism is therefore precise:

This inference is too strong for the data and method used.

That is more scientifically defensible than claiming that all neuroscience has failed.

Conclusion

The lesson is simple: a brain map is not the brain, and a brain signal is not a direct readout of the mind. fMRI should be understood as one useful but limited method for studying systems-level brain physiology. Users should resist visual overinterpretation; critics should avoid turning real methodological limitations into a total rejection of neuroscience.

This problem is not unique to functional neuroimaging. Across medical science, technologies can generate highly persuasive measurements, images, biomarkers, algorithms, and statistical associations that are interpreted more confidently than their validity, reproducibility, or clinical utility warrants. Researchers themselves widely recognize this broader challenge: a 2024 survey found that 72% of biomedical researchers agreed that biomedicine faces a reproducibility crisis. 

The video discussed in this article is therefore only one example. It should draw the attention of everyone working in medicine—clinicians, investigators, educators, reviewers, journal editors, and policymakers—to a common responsibility: distinguish a measurement from the biological reality it approximates, an association from a cause, and an interesting research finding from a clinically validated conclusion. Scientific progress depends not only on creating more advanced technologies, but also on applying them with methodological humility, transparent validation, independent replication, and attention to the patient rather than to the image alone.

Andriy Yabluchanskiy together with Mykola Iabluchanskyi